All Stories

  1. Concordance between bone marrow and blood measurable residual disease after first-line novel agent treatment for chronic lymphocytic leukemia: a systematic review and meta-analysis
  2. Neutropenic Diet Versus Liberalized Diet in Patients With Cancer: A Systematic Review and Meta-Analysis
  3. Impact of Conditioning Regimen Intensity and Total Body Irradiation on Outcomes of Allogeneic Hematopoietic Cell Transplantation for Mature T-Cell Lymphomas: A Multicenter Analysis
  4. Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing
  5. Real-world outcomes of cilta-cel versus BCMA-targeting bispecific antibodies in relapsed/refractory multiple myeloma
  6. At the Crossroads of Lineage: Secondary Malignancies After CAR-Based Immunotherapy
  7. Trends in the design of FDA registrational randomised clinical trials in haematology and oncology: a 20-year cohort study
  8. Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial
  9. Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access
  10. Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access
  11. Chimeric antigen receptor T‐cell therapy for high‐grade B‐cell lymphoma NOS
  12. SGLT2 inhibitors and cardiovascular outcomes in patients with multiple myeloma and concomitant type 2 diabetes mellitus
  13. Estimation of Benefit to Bispecific Antibodies in US Patients with Lymphoma and Multiple Myeloma
  14. Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis
  15. CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma
  16. IgG replacement in multiple myeloma
  17. Relationships Among Health Insurance Literacy, Financial Toxicity, and Sociodemographic Factors in Patients With Cancer
  18. Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma
  19. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice
  20. Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B-Cell Lymphoma: Evolving Role in the Era of CAR T-Cell Therapy
  21. Quality of the control arms in randomized trials of chronic lymphocytic leukemia enrolling in the USA: A systematic review
  22. Isolated CNS relapse of blastic plasmacytoid dendritic cell neoplasm
  23. Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity
  24. Primary Central Nervous System Lymphoma: Consensus, Controversies and Future Directions
  25. Change in 21‐gene Recurrence Score result after exposure to neo‐adjuvant endocrine therapy in patients with operable breast cancer
  26. Gone But Here
  27. Clinical features and cell of origin subtyping using gene expression profiling in HIV-negative patients with primary central nervous system lymphoma
  28. Hemostatic complications associated with ventricular assist devices
  29. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration
  30. Hanging Up the Gloves
  31. Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis
  32. Germ Cell Tumors with Malignant Somatic Transformation: A Mayo Clinic Experience
  33. Erratum
  34. Outcome disparities in colorectal cancer: a SEER-based comparative analysis of racial subgroups
  35. ASO Author Reflections: Role of Contrast-Enhanced Spectral Mammography in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy
  36. I Don’t Know
  37. Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission
  38. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis
  39. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections
  40. Activity Of Imatinib In Clonal Extramedullary Myeloid Neoplasms With Eosinophilia
  41. Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy
  42. Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia—the Burden of Novelty
  43. Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma
  44. Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis
  45. Brentuximab Vedotin for Stage III or IV Hodgkin’s Lymphoma
  46. Necrobiotic xanthogranuloma: a 30-year single-center experience
  47. Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy
  48. Nivolumab-associated bone marrow necrosis
  49. A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma
  50. Myeloid neoplasm with eosinophilia associated with isolated extramedullary FIP1L1 / PDGFRA rearrangement
  51. B-cell acute lymphoblastic leukemia with +der(1)t(1;19) (p13;p13.1) arising in the setting of CALR exon 9 mutated essential thrombocythemia
  52. Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy
  53. Cytomegalovirus reactivation is associated with a lower rate of early relapse in myeloid malignancies independent of in-vivo T cell depletion strategy
  54. Update on lung neuroendocrine tumors
  55. ERBB2 (HER2)Testing in Breast Cancer
  56. Radiation-induced breast cancer: the question of early breast cancer screening in Hodgkin's lymphoma survivors
  57. Unexpected Cardiac Masses
  58. Exploring the possibilities: airspace disease in the postallogeneic haematopoietic stem cell transplant period
  59. The Perils of Country Life: Human Monocytic Ehrlichiosis
  60. Maintaining sharp focus on a grainy film: miliary pattern in an elderly woman with acute respiratory failure
  61. Sudden cardiac arrest in a healthy young athlete
  62. Bilateral upper lobe opacification
  63. Diffuse unresolving pulmonary nodules in a patient with a history of cervical carcinoma
  64. A tick-borne illness unmasking asymptomatic Brugada syndrome
  65. Fatal Cytomegalovirus Disease after Combination Therapy with Corticosteroids and Rituximab for Granulomatosis with Polyangiitis
  66. Disseminated tuberculosis with tuberculous meningitis in an immunocompetent host
  67. Chronic rupture of the coronary sinus of Valsalva with pseudoaneurysm formation
  68. A cause to consider for chronic unresolving diarrhea
  69. Fulminant Wilson’s Disease Managed with Plasmapheresis as a Bridge to Liver Transplant
  70. Isolated neurocutaneous peripheral T cell lymphoma, NOS